hotspot -WSS

hotspot

author：focus 2025-10-01 05:38:22 - browse：27894

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Free Covid tests will again be offered to all U.S. households

focus

WSS

Midwives could help bridge maternal health disparities in the U.S.

Grad students accuse University of California of wage theft

'Vaccine

STAT Madness 2024: Meet the contenders

How the messy conversation about Dolly changed bioethics

People with substance use disorder deserve online privacy

leisure time

hotspot

entertainment

Sports medicine is finally prioritizing gender equality

Midwives could help bridge maternal health disparities in the U.S.

ChatGPT in medicine: STAT answers readers' burning questions

Using force crossed my mind when examining a defiant young patient

Psychedelics group wrestles with new pharma identity

Eli Lilly CEO gives to Mike Pence presidential super PAC

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

How the messy conversation about Dolly changed bioethics

Medical leaders decry Supreme Court decision on affirmative action

Study fuels hope CAR

Wikipedia

Information blocking fines are now fair game in health care

FDA weighs limits of animal data in assessing artificial wombs

Children’s Hospital revives plan for pedestrian bridge

Children’s Hospital revives plan for pedestrian bridge

Medicare isn't yet testing food as medicine

Laying a path for careers in science

hotspot

hotspot

focus

Wikipedia